Ho-Yeong Lim

Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study

Josep M. Llovet, Thomas Decaens, Jean‐Luc Raoul et al. · Journal of Clinical Oncology · 2013 · 592 citations · Full text

Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC).

Richard S. Finn, Baek‐Yeol Ryoo, Philippe Merle et al. · Journal of Clinical Oncology · 2019 · 210 citations

Pathology, Pharmacotherapy, Oncology +20

Prediction of Disease-free Survival in Hepatocellular Carcinoma by Gene Expression Profiling

Ho-Yeong Lim, Insuk Sohn, Shibing Deng et al. · Annals of Surgical Oncology · 2013 · 150 citations

Hepatology, Hepatocellular Carcinoma, Medicine +11

1398 BRIVANIB VERSUS PLACEBO IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC) WHO FAILED OR WERE INTOLERANT TO SORAFENIB: RESULTS FROM THE PHASE 3 BRISK-PS STUDY

Josep M. Llovet, Thomas Decaens, Jean‐Luc Raoul et al. · Journal of Hepatology · 2012 · 100 citations

Oncology, Hepatology, Clinical Trials +11

Rapamycin-insensitive companion of mTOR (RICTOR) amplification defines a subset of advanced gastric cancer and is sensitive to AZD2014-mediated mTORC1/2 inhibition

S. T. Kim, Su‐Young Kim, Samuel J. Klempner et al. · Annals of Oncology · 2016 · 72 citations · Full text

Tumor Biology, Oncology, Gastrointestinal Oncology +9